<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220113</url>
  </required_header>
  <id_info>
    <org_study_id>2017/05/1</org_study_id>
    <nct_id>NCT03220113</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Migraine Headaches.</brief_title>
  <acronym>Migraine</acronym>
  <official_title>Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corona Doctors Medical Clinics, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corona Doctors Medical Clinics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in
      the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of
      simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the
      trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one
      session.

      Patients who meet the exclusion and inclusion criteria are eligible for trial if they have
      experienced chronic migraine and craniofacial pain not responding to other prior therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A combination of dexamethasone, lidocaine and thiamine (pat.), may bring changes in the
      pattern of sympathetic and parasympathetic nerve signaling at the level vasa nervorum. These
      changes may down-regulate the hyperexcitable sympathetic signals at the level of adventitia
      and consequently the medial layer of vasa nervorum and providing long term relief from
      migraine headaches. However, a bilateral and simultaneous treatment of trigeminal and
      occipital nerves in migraine and craniofacial neuralgia using a combination of dexamethasone,
      thiamine and lidocaine has been rarely studied.

      The objective of this study is to assess the safety and efficacy of concomitant
      administration of dexamethasone, lidocaine, and thiamine compounds into the trigeminal nerve
      branches, the greater and lesser occipital nerve for the treatment of chronic migraine, and
      craniofacial neuralgia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective Open Label Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the safety to the De-Novo treatment formula in study patients</measure>
    <time_frame>5 weeks</time_frame>
    <description>Study assesses the safety of the De-Novo algorithm( if patients who receive this treatment will experience any major adverse reactions due to the medication combination )within the next 5 weeks following treatment. Participants will be interviewed after the initial treatment weekly, for 5 weeks to evaluate for any possible adverse events, hospitalization, or treatment. Any significant adverse event in over 45% of participants, may project end of the trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the clinical response to the De-Novo treatment formula in study patients consisting of a lone composite measure</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of the clinical response to the De-Novo treatment formula in study patients.
Study assesses the efficacy parameters of the study ( i.e. the change in baseline frequency of migraine attack in patients post initial treatment ), and functionality status based on continuation of work performance and return to work or school.
Therefore, the Outcome of study consisting of multiple measures and present lone composite measure.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Migraine Without Aura, Intractable</condition>
  <condition>Migraine With Typical Aura</condition>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Dexamethasone,Lidocaine,Thiamine cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.
De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Dexamethasone, Lidocaine, Thiamine cohort</intervention_name>
    <description>Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.</description>
    <arm_group_label>Dexamethasone,Lidocaine,Thiamine cohort</arm_group_label>
    <other_name>De-Novo Treatment Cohort medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Age: 10-90 years

               -  Ability to describe headache and its symptoms

               -  Ability to read, comprehend, and legibly and reliably record information

               -  Ability to provide written, informed consent, and respond to pre and post
                  treatment questionnaires, children's guardian accepts responsibility. Willingness
                  and ability to comply with the study scheduled visits, treatment plans,
                  laboratory tests and other procedures

               -  Already diagnosed with chronic craniofacial neuralgia and chronic migraine
                  headache

               -  Exhausted all or most of available abortive and preventive treatment modalities.

        Exclusion Criteria:

          -  • Uncontrollable hypertension, acute Myocardial Infarct within last 6 months

               -  History of cerebral vascular aneurysm/known atherosclerosis of cerebral system,
                  brain tumor

               -  Implanted of neuro-stimulator, trigeminal tractotomy, neurectomy partial or
                  complete, history of gamma knife treatment, microsurgical decompression
                  procedure.

               -  Hypersensitivity or allergy to any components of De-Novo formula

               -  Presence or known anatomic craniofacial deformities or severe
                  spondylosis/spondylolisthesis of cervical spine, profound dental caries,
                  Maxillofacial deformities

               -  Pregnancy and current breast feeding status

               -  Headaches attribute to acute head and neck injuries, chronicity of cervicogenic
                  headaches

               -  Skin infection or micro abscesses dermatogen or dental, ongoing treatment for
                  Methicillin Resistant Streptococcus Aureus ( MRSA) unless treatment completed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faro T. Owiesy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Corona Doctors Medical Clinics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faro T. Owiesy, M.D.</last_name>
    <phone>9513719500</phone>
    <email>owiesymd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jovana Martin Murillo</last_name>
    <phone>9513719500</phone>
    <email>coronadoctors@aol.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corona Doctors Medical Clinics Inc</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faro T Owiesy</last_name>
      <phone>951-371-9500</phone>
      <email>owiesymd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jovana Martin Murillo</last_name>
      <phone>9513719500</phone>
      <email>coronadoctors@aol.com</email>
    </contact_backup>
    <investigator>
      <last_name>Faro T Owiesy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007 May;6(5):442-55. Review.</citation>
    <PMID>17434099</PMID>
  </reference>
  <reference>
    <citation>Negovskiĭ VA. [History of resuscitation in the USSR]. Vestn Akad Med Nauk SSSR. 1975;(12):26-9. Russian.</citation>
    <PMID>775837</PMID>
  </reference>
  <reference>
    <citation>Johri S, Shetty S, Soni A, Kumar S. Anaphylaxis from intravenous thiamine--long forgotten? Am J Emerg Med. 2000 Sep;18(5):642-3.</citation>
    <PMID>10999594</PMID>
  </reference>
  <reference>
    <citation>Morinville V, Jeannet-Peter N, Hauser C. Anaphylaxis to parenteral thiamine (vitamin B1). Schweiz Med Wochenschr. 1998 Oct 31;128(44):1743-4.</citation>
    <PMID>9846348</PMID>
  </reference>
  <reference>
    <citation>Van Haecke P, Ramaekers D, Vanderwegen L, Boonen S. Thiamine-induced anaphylactic shock. Am J Emerg Med. 1995 May;13(3):371-2. Review.</citation>
    <PMID>7755837</PMID>
  </reference>
  <reference>
    <citation>Wrenn KD, Murphy F, Slovis CM. A toxicity study of parenteral thiamine hydrochloride. Ann Emerg Med. 1989 Aug;18(8):867-70.</citation>
    <PMID>2757284</PMID>
  </reference>
  <reference>
    <citation>De Bold JF, Ruppert PH, Clemens LG. Inhibition of estrogen-induced sexual receptivity of female hamsters: comparative effects of progesterone, dihydrotestosterone and an estrogen antagonist. Pharmacol Biochem Behav. 1978 Jul;9(1):81-6.</citation>
    <PMID>704656</PMID>
  </reference>
  <reference>
    <citation>Hayashi Y. Effects of intra-amygdaloid injections of alpha-difluoromethylornithine and putrescine on the development of electrical kindling in rats. Brain Res. 1991 Sep 27;560(1-2):181-5.</citation>
    <PMID>1760726</PMID>
  </reference>
  <reference>
    <citation>Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med. 2012 Jan 1;52(1):182-90. doi: 10.1016/j.freeradbiomed.2011.10.444. Epub 2011 Oct 24.</citation>
    <PMID>22067901</PMID>
  </reference>
  <reference>
    <citation>Newman SP. Aerosol deposition considerations in inhalation therapy. Chest. 1985 Aug;88(2 Suppl):152S-160S. Review.</citation>
    <PMID>3893925</PMID>
  </reference>
  <reference>
    <citation>Yadav UC, Kalariya NM, Srivastava SK, Ramana KV. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med. 2010 May 15;48(10):1423-34. doi: 10.1016/j.freeradbiomed.2010.02.031. Epub 2010 Feb 26.</citation>
    <PMID>20219672</PMID>
  </reference>
  <reference>
    <citation>Yadav UC, Subramanyam S, Ramana KV. Prevention of endotoxin-induced uveitis in rats by benfotiamine, a lipophilic analogue of vitamin B1. Invest Ophthalmol Vis Sci. 2009 May;50(5):2276-82. doi: 10.1167/iovs.08-2816. Epub 2009 Jan 10.</citation>
    <PMID>19136698</PMID>
  </reference>
  <reference>
    <citation>Tai HH, Tong M, Ding Y. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. Prostaglandins Other Lipid Mediat. 2007 May;83(3):203-8. Epub 2007 Jan 17. Review.</citation>
    <PMID>17481556</PMID>
  </reference>
  <reference>
    <citation>Liu S, Stromberg A, Tai HH, Moscow JA. Thiamine transporter gene expression and exogenous thiamine modulate the expression of genes involved in drug and prostaglandin metabolism in breast cancer cells. Mol Cancer Res. 2004 Aug;2(8):477-87.</citation>
    <PMID>15328374</PMID>
  </reference>
  <reference>
    <citation>Rodríguez Meléndez R. [Importance of water-soluble vitamins as regulatory factors of genetic expression]. Rev Invest Clin. 2002 Jan-Feb;54(1):77-83. Review. Spanish.</citation>
    <PMID>11995411</PMID>
  </reference>
  <reference>
    <citation>Bettendorff L, Wins P. Thiamin diphosphate in biological chemistry: new aspects of thiamin metabolism, especially triphosphate derivatives acting other than as cofactors. FEBS J. 2009 Jun;276(11):2917-25. doi: 10.1111/j.1742-4658.2009.07019.x. Epub 2009 Apr 23. Review.</citation>
    <PMID>19490098</PMID>
  </reference>
  <reference>
    <citation>Hazell AS, Butterworth RF. Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. Alcohol Alcohol. 2009 Mar-Apr;44(2):141-7. doi: 10.1093/alcalc/agn120. Epub 2009 Jan 16. Review.</citation>
    <PMID>19151161</PMID>
  </reference>
  <reference>
    <citation>Desjardins P, Butterworth RF. Role of mitochondrial dysfunction and oxidative stress in the pathogenesis of selective neuronal loss in Wernicke's encephalopathy. Mol Neurobiol. 2005;31(1-3):17-25. Review.</citation>
    <PMID>15953809</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Craniofacial Neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No sharing suggested at this time</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

